IDEAYA Biosciences Inc (IDYA)
36.55
+0.76
(+2.12%)
USD |
NASDAQ |
May 31, 16:00
36.60
+0.05
(+0.14%)
After-Hours: 20:00
IDEAYA Biosciences Enterprise Value: 2.068B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 2.068B |
| May 30, 2024 | 2.010B |
| May 29, 2024 | 2.019B |
| May 28, 2024 | 2.142B |
| May 24, 2024 | 2.155B |
| May 23, 2024 | 2.211B |
| May 22, 2024 | 2.433B |
| May 21, 2024 | 2.404B |
| May 20, 2024 | 2.353B |
| May 17, 2024 | 2.367B |
| May 16, 2024 | 2.444B |
| May 15, 2024 | 2.513B |
| May 14, 2024 | 2.465B |
| May 13, 2024 | 2.410B |
| May 10, 2024 | 2.417B |
| May 09, 2024 | 2.377B |
| May 08, 2024 | 2.435B |
| May 07, 2024 | 2.537B |
| May 06, 2024 | 2.563B |
| May 03, 2024 | 2.494B |
| May 02, 2024 | 2.403B |
| May 01, 2024 | 2.380B |
| April 30, 2024 | 2.340B |
| April 29, 2024 | 2.340B |
| April 26, 2024 | 2.287B |
| Date | Value |
|---|---|
| April 25, 2024 | 2.189B |
| April 24, 2024 | 2.281B |
| April 23, 2024 | 2.219B |
| April 22, 2024 | 2.112B |
| April 19, 2024 | 2.077B |
| April 18, 2024 | 2.114B |
| April 17, 2024 | 2.305B |
| April 16, 2024 | 2.379B |
| April 15, 2024 | 2.405B |
| April 12, 2024 | 2.439B |
| April 11, 2024 | 2.550B |
| April 10, 2024 | 2.464B |
| April 09, 2024 | 2.484B |
| April 08, 2024 | 2.441B |
| April 05, 2024 | 2.479B |
| April 04, 2024 | 2.396B |
| April 03, 2024 | 2.453B |
| April 02, 2024 | 2.404B |
| April 01, 2024 | 2.480B |
| March 28, 2024 | 2.747B |
| March 27, 2024 | 2.704B |
| March 26, 2024 | 2.644B |
| March 25, 2024 | 2.630B |
| March 22, 2024 | 2.683B |
| March 21, 2024 | 2.877B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-37.31M
Minimum
Mar 17 2020
2.989B
Maximum
Feb 16 2024
572.00M
Average
341.54M
Median
Enterprise Value Benchmarks
| Merck & Co Inc | 346.63B |
| Pfizer Inc | 219.46B |
| Bristol-Myers Squibb Co | 129.36B |
| Arvinas Inc | 1.101B |
| BridgeBio Pharma Inc | 6.450B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.06M |
| Total Expenses (Quarterly) | 51.02M |
| EPS Diluted (Quarterly) | -0.53 |
| Earnings Yield | -5.50% |
| Normalized Earnings Yield | -5.473 |